跳转至内容
Merck

F6432

Sigma-Aldrich

FLT3 (571-993), active, GST tagged human

PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

别名:

CD135, FLK2, STK1

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12352200
NACRES:
NA.32

重組細胞

expressed in baculovirus infected Sf9 cells

品質等級

產品線

PRECISIO® Kinase

化驗

≥70% (SDS-PAGE)

形狀

buffered aqueous glycerol solution

比活性

60-81 nmol/min·mg

分子量

~73 kDa

UniProt登錄號

運輸包裝

dry ice

儲存溫度

−70°C

基因資訊

human ... FLT3(2322)

一般說明

FLT3 (fms-related tyrosine kinase 3) is a tyrosine kinase receptor and the gene is localized to human chromosome 13q12. The encoded protein is composed of 993 amino acids, and consists of five immunoglobulin (Ig)-like domains in its exoplasmic region. It is also composed of a transmembrane region, a juxtamembrane domain, and two tyrosine kinase domains in its intracellular domain. The tyrosine kinase domains are linked via a kinase-insert domain.

生化/生理作用

FLT3 (fms-related tyrosine kinase 3), upon interaction with its ligand, undergoes conformational changes to form homodimers. This results in phosphorylation and activation of downstream signaling pathways including phosphatidylinositol 3-kinase (PI3K/AKT), mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and signal transducer and activator of transcription 5 (STAT5) pathways. Internal tandem duplication (ITD) mutation or a point mutation in juxtamembrane domain-coding region or within the activation loop domain, respectively, of this gene lead to its constitutive action. FLT3/ITD mutation is associated with later stages of acute myeloid leukemia (AML) pathogenesis. These patients have poor prognosis.

外觀

Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.

法律資訊

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Aquatic Chronic 3 - Eye Irrit. 2 - Skin Sens. 1

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

D Gary Gilliland et al.
Current opinion in hematology, 9(4), 274-281 (2002-06-04)
FLT3 is the most frequently mutated gene in cases of acute myelogenous leukemia (AML). About 30 to 35% of patients have either internal tandem duplications (ITDs) in the juxtamembrane domain or mutations in the activating loop of FLT3. FLT3 mutations
J L Christensen et al.
Proceedings of the National Academy of Sciences of the United States of America, 98(25), 14541-14546 (2001-11-29)
Clonogenic multipotent mouse hematopoietic stem cells (HSCs) and progenitor cells are contained within the c-kit(+) (K) lineage(-/lo) (L) Sca-1(+) (S) population of hematopoietic cells; long-term (LT) and short-term (ST) HSCs are Thy-1.1(lo). c-kit is a member of the receptor tyrosine
Alexa S Green et al.
Science advances, 1(8), e1500221-e1500221 (2015-11-26)
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide short-term disease control, but relapse invariably occurs within months. Pim
D L Stirewalt et al.
Blood cancer journal, 4, e208-e208 (2014-05-03)
Patients with high FLT3 internal tandem duplication allelic ratios (FLT3/ITD-ARs) have a poor prognosis. Single-nucleotide polymorphism/comparative genomic hybridization, single-cell PCR and colony-forming assays were used to evaluate genotypic evolution of high FLT3/ITD-ARs in 85 acute myeloid leukemia (AML) patients. Microarrays
Yesid Alvarado et al.
Cancer, 120(14), 2142-2149 (2014-04-17)
FLT3-internal tandem duplication (ITD) mutations are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 inhibitors have shown clinical activity in AML with FLT3-ITD, but responses are usually short-lived. This study examined 69 FLT3-mutated patients with AML

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门